Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3847861 | American Journal of Kidney Diseases | 2014 | 11 Pages |
Abstract
Part D net costs for CKD-MBD medications increased at a faster rate than costs for all Part D medications in dialysis patients despite relatively stable use within medication classes. In a bundled environment, there may be incentives to shift to generic phosphate binders and reduce cinacalcet use.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Akeem A. PhD, Benjamin L. PhD, Christopher A. PharmD, Wendy L. PharmD,